Clinical Pharmacokinetics of the PDT Photosensitizers Porfimer Sodium (Photofrin), 2‐[1‐Hexyloxyethyl]‐2‐Devinyl Pyropheophorbide‐a (Photochlor) and 5‐ALA‐Induced Protoporphyrin IX

Photodynamic therapy (PDT) uses a photosensitizer activated by light, in an oxygen‐rich environment, to destroy malignant tumors. Clinical trials of PDT at Roswell Park Cancer Institute (RPCI) use the photosensitizers Photofrin, Photochlor, and 5‐ALA‐induced protoporphyrin IX (PpIX). In some studies the concentrations of photosensitizer in blood, and occasionally in tumor tissue, were obtained. Pharmacokinetic (PK) data from these individual studies were pooled and analyzed. This is the first published review to compare head‐to‐head the PK of Photofrin and Photochlor.

[1]  T J Dougherty,et al.  Intracavitary photodynamic therapy for malignant pleural mesothelioma. , 1995, Seminars in surgical oncology.

[2]  Michael J. Emanuele,et al.  Hypoxia and Photofrin Uptake in the Intraperitoneal Carcinomatosis and Sarcomatosis of Photodynamic Therapy Patients , 2004, Clinical Cancer Research.

[3]  Kevin M. Smith,et al.  CHLORIN AND PORPHYRIN DERIVATIVES AS POTENTIAL PHOTOSENSITIZERS IN PHOTODYNAMIC THERAPY , 1991, Photochemistry and photobiology.

[4]  E. Reddi,et al.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. , 1984, Cancer letters.

[5]  A. Anstey,et al.  Bowen’s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large‐field incoherent light source , 2001, The British journal of dermatology.

[6]  Hector Nava,et al.  Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. , 2003, Cancer research.

[7]  Hector Nava,et al.  Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy , 2005, Cancer Chemotherapy and Pharmacology.

[8]  T J Dougherty,et al.  DISTRIBUTION AND ELIMINATION OF PHOTOFRIN II IN MICE , 1989, Photochemistry and photobiology.

[9]  A. Straughn,et al.  Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. , 2002, The Journal of pharmacology and experimental therapeutics.

[10]  R. Pottier,et al.  On the role of protoporphyrin IX photoproducts in photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.

[11]  J. Kennedy,et al.  The Monitoring of ALA-Induced Protoporphyrin IX Accumulation and Clearance in Patients with Skin Lesions by In Vivo Surface-Detected Fluorescence Spectroscopy , 1999, Lasers in Medical Science.

[12]  T. Dougherty,et al.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. , 1979, Cancer research.

[13]  D. Bellnier,et al.  Photosensitization and split-dose recovery in cultured human urinary bladder carcinoma cells containing nonexchangeable hematoporphyrin derivative. , 1985, Cancer research.

[14]  Mosteller Rd.  Simplified Calculation of Body-Surface Area , 1987 .

[15]  K. Rauch,et al.  The photochemistry of 3,5,3',5'-tetrasubstituted stilbenes : formation of an equilibrium mixture of isomeric 4,4'-dihydrophenanthrene derivatives , 1989 .

[16]  T J Dougherty,et al.  A preliminary pharmacokinetic study of intravenous Photofrin in patients. , 1996, Journal of clinical laser medicine & surgery.

[17]  A. Oseroff,et al.  Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. , 2005, Archives of dermatology.

[18]  H. S. de Bruijn,et al.  Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice. , 1996, British Journal of Cancer.

[19]  T. Dougherty,et al.  An Assay for the Quantitation of Photofrin in Tissues and Fluids , 1997, Photochemistry and photobiology.

[20]  F. Hillenkamp,et al.  Comparative mass spectrometric analyses of Photofrin oligomers by fast atom bombardment mass spectrometry, UV and IR matrix-assisted laser desorption/ionization mass spectrometry, electrospray ionization mass spectrometry and laser desorption/jet-cooling photoionization mass spectrometry. , 1999, Journal of mass spectrometry : JMS.

[21]  T J Dougherty,et al.  Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. , 1994, The Annals of thoracic surgery.

[22]  D. Kessel.  Components of hematoporphyrin derivatives and their tumor-localizing capacity. , 1982, Cancer research.

[23]  T. Dougherty,et al.  Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. , 1993, Journal of photochemistry and photobiology. B, Biology.

[24]  J. Kennedy,et al.  Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.

[25]  J. Carruth,et al.  CLINICAL APPLICATIONS OF PHOTODYNAMIC THERAPY , 1991, International journal of clinical practice.